EVALUATE RISK/BENEFIT OF NAB PACLITAXEL IN COMBINATION WITH GEMCITABINE AND CARBOPLATIN COMPARED TO GEMCITABINE AND CARBOPLATIN IN TRIPLE NEGATIVE METASTATIC BREAST CANCER (OR METASTATIC TRIPLE NEGATIVE BREAST CANCER):